Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 9/20 | 0.78 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.78 |
| ▸ | ITGAL | P20701 | 9/20 | 0.78 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.77 |
| ▸ | CTSL | P07711 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | ACE | P12821 | 2/20 | 0.68 |
| ▸ | TACR1 | P25103 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616778 | 1.00 | ITGB2 (0.78) | ITGB2ICAM1ITGALERAP2CTSL | |
| SCHEMBL5191302 | 1.00 | ITGB2 (0.78) | ITGB2ICAM1ITGALERAP2CTSL | |
| SCHEMBL9466705 | 1.00 | ITGB2 (0.78) | ITGB2ICAM1ITGALERAP2CTSL | |
| SCHEMBL22206878 | 0.99 | ITGB2 (0.77) | ITGB2ICAM1ITGALERAP2CTSL | |
| SCHEMBL22206876 | 0.99 | ITGB2 (0.77) | ITGB2ICAM1ITGALERAP2CTSL | |
| SCHEMBL11870861 | 0.94 | ERAP2 (0.76) | ITGB2ICAM1ITGALERAP2CTSL | |
| SCHEMBL9828348 | 0.93 | ERAP2 (0.74) | ITGB2ICAM1ITGALERAP2CTSL | |
| SCHEMBL9828342 | 0.93 | ERAP2 (0.74) | ITGB2ICAM1ITGALERAP2CTSL | |
| SCHEMBL23092632 | 0.92 | ITGB2 (0.81) | ITGB2ICAM1ITGALERAP2CTSL | |
| SCHEMBL21623652 | 0.92 | ERAP2 (0.72) | ITGB2ICAM1ITGALERAP2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4283337-A | Process for the purification of tryptophane and derivatives of tryptophane | DEUTSCHE GOLD UND- SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-08-11 | — | — | US | claimed |
| CN-112438905-B | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3374027-B1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | UNIV COLUMBIA (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112438905-A | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-10925857-B2 | Rational drug design targeting resistant gram-negative bacterial infections to polymyxin-class antibiotics | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-02-23 | — | — | US | disclosed |
| CN-106687457-B | Heteroaryl compounds for kinase inhibition | 阿里亚德医药股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20190231747-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-08-01 | — | — | US | disclosed |
| WO-2017083859-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-18 | — | — | WO | disclosed |
| CN-101087585-A | Reduction of hair growth | GILLETTE CO (US) | 2007-12-12 | — | — | CN | disclosed |
| EP-1338588-B1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORP (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-4745124-A | THIO/ESTER PEPTIDES | UNIVERSITY OF MIAMI (US) | 1988-05-17 | — | — | US | disclosed |
| EP-0134561-B1 | ALPHA-ALLENIC-ALPHA-AMINO ACIDS | SYNTEX (U.S.A.) INC. (US) | 1987-07-08 | — | — | EP | disclosed |
| US-4661510-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0134561-A1 | Alpha-allenic-alpha-amino acids | SYNTEX (U.S.A.) INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| EP-0052200-B1 | CYCLIC ACETALS OF N-ACYLATED GLUTAMIC ACID GAMMA-SEMIALDEHYDES, PROCESS FOR THEIR PREPARATION AND THEIR USE | Degussa Aktiengesellschaft (DE) | 1984-06-06 | — | — | EP | disclosed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | disclosed |
| US-4424370-A | N-ACYLTRYPTOPHANE INTERMEDIATES | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1984-01-03 | — | — | US | disclosed |
| EP-0052200-A1 | Cyclic acetals of N-acylated glutamic acid gamma-semialdehydes, process for their preparation and their use | Degussa Aktiengesellschaft (DE) | 1982-05-26 | — | — | EP | disclosed |
| EP-0036713-A2 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-30 | — | — | EP | disclosed |
| US-4283337-A | Process for the purification of tryptophane and derivatives of tryptophane | DEUTSCHE GOLD UND- SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231747-A1 | RATIONAL DRUG DESIGN TARGETING RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS TO POLYMYXIN-CLASS ANTIBIOTICS | APRT, NMT2, NMT1 | ITGB2 2649/4885ICAM1 4210/4885ITGAL 3631/4885 |
| US-10925857-B2 | Rational drug design targeting resistant gram-negative bacterial infections to polymyxin-class antibiotics | APRT, NMT2, NMT1 | ITGB2 2649/4885ICAM1 4210/4885ITGAL 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.